Company intelligence / Profile preview

Elpiscience

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Phase 1

Overview

Elpiscience has a robust pipeline of more than ten innovative molecules focused on cancer immunotherapy and autoimmune diseases. Its leading assets, ES101 and ES102, are both in Phase I clinical trials. Three additional first-in-class candidates are currently undergoing IND-enabling studies. The company leverages proprietary antibody discovery technologies to address unmet needs in oncology and autoimmunity.[1][2][3]

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)Other biologics (immunotherapies)
Industry: Biotech

Drug pipeline

15 assets

ES014

14 more assets in the full pipeline.

Request access →

Partnerships

Global strategic partnerships mentioned but specific partners not named publicly as of current data[2].

Beyond the preview

Go deeper on Elpiscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elpiscience.

Explore the full profile